Careers Contact Locations

OPKO Health, Inc.

  • Home
  • Who We Are
    • Our Vision
    • Our History
    • Our Leadership
  • What We Do
    • Overview
    • Our Products
    • Our Solutions
    • Our Technology
    • Our Research
    • Our Diagnostics
  • News & Media
    • Press Releases
    • Announcements
    • Events
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact
  • Locations

Press Releases

News & Media

News & Media

  • Press Releases
  • Announcements
  • Events
  • Presentations

OPKO Health, Inc. Announces Proposed Offering of Common Stock

Oct 22, 2019

OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

Oct 21, 2019

OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

Aug 29, 2019

OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results

Aug 7, 2019

OPKO Health to Report Second Quarter 2019 Financial Results on August 7, 2019

Aug 1, 2019

OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers

Jul 1, 2019

Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test

Jun 28, 2019

OPKO Health Submits De Novo Request to the U.S. FDA for the 4Kscore® Test

Jun 20, 2019

OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results

May 7, 2019

OPKO Health to Report First Quarter 2019 Financial Results on May 7, 2019

Apr 30, 2019
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...43
    Next
    © 2021 OPKO Health, Inc. All Rights Reserved.
    Privacy Policy Governance Terms of Use Sitemap